Phosphorylation of the Neurospora Clock Protein FREQUENCY Determines its Degradation Rate and Strongly Influences the Period Length of the Circadian Clock by Liu, Yi et al.
Dartmouth College 
Dartmouth Digital Commons 
Open Dartmouth: Published works by 
Dartmouth faculty Faculty Work 
1-4-2000 
Phosphorylation of the Neurospora Clock Protein FREQUENCY 
Determines its Degradation Rate and Strongly Influences the 





Jay C. Dunlap 
Dartmouth College 
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa 
 Part of the Medical Genetics Commons 
Dartmouth Digital Commons Citation 
Liu, Yi; Loros, Jennifer; and Dunlap, Jay C., "Phosphorylation of the Neurospora Clock Protein FREQUENCY 
Determines its Degradation Rate and Strongly Influences the Period Length of the Circadian Clock" 
(2000). Open Dartmouth: Published works by Dartmouth faculty. 1509. 
https://digitalcommons.dartmouth.edu/facoa/1509 
This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has 
been accepted for inclusion in Open Dartmouth: Published works by Dartmouth faculty by an authorized 
administrator of Dartmouth Digital Commons. For more information, please contact 
dartmouthdigitalcommons@groups.dartmouth.edu. 
Phosphorylation of the Neurospora clock protein
FREQUENCY determines its degradation rate
and strongly influences the period length
of the circadian clock
Yi Liu*, Jennifer Loros, and Jay C. Dunlap†
Department of Genetics, Dartmouth Medical School, Hanover, NH 03755
Edited by David D. Perkins, Stanford University, Stanford, CA, and approved November 12, 1999 (received for review September 3, 1999)
Under free running conditions, FREQUENCY (FRQ) protein, a central
component of the Neurospora circadian clock, is progressively
phosphorylated, becoming highly phosphorylated before its deg-
radation late in the circadian day. To understand the biological
function of FRQ phosphorylation, kinase inhibitors were used to
block FRQ phosphorylation in vivo and the effects on FRQ and the
clock observed. 6-dimethylaminopurine (a general kinase inhibitor)
is able to block FRQ phosphorylation in vivo, reducing the rate of
phosphorylation and the degradation of FRQ and lengthening the
period of the clock in a dose-dependent manner. To confirm the
role of FRQ phosphorylation in this clock effect, phosphorylation
sites in FRQ were identified by systematic mutagenesis of the FRQ
ORF. The mutation of one phosphorylation site at Ser-513 leads to
a dramatic reduction of the rate of FRQ degradation and a very long
period (>30 hr) of the clock. Taken together, these data strongly
suggest that FRQ phosphorylation triggers its degradation, and the
degradation rate of FRQ is a major determining factor for the
period length of the Neurospora circadian clock.
C ircadian clocks are found in almost all groups of organisms,and they control a wide variety of daily ('24-hr) endogenous
(circadian) rhythms of molecular, physiological, and behavioral
activities in these organisms (1). The identification of clock genes
in several model systems and the understanding of how these
genes are regulated have greatly enhanced our knowledge of how
circadian clocks work at the molecular level (1–8). Common
themes of clock mechanisms have begun to emerge: clock
components comprising a core of the oscillator are part of a
network of positive and negative interactions that establish a
negative feedback loop that is essential for circadian oscillation
(1, 9–16).
The Neurospora circadian oscillator comprises an autoregula-
tory negative feedback cycle in which frq mRNA and FRQ
protein are the central components (1, 17, 18). Mutations at the
frq locus cause a variety of clock phenotypes: long and short
period length (16–29 hr), arrhythmia, and loss of temperature
and nutritional compensation of the clock; the deletion of the frq
locus results in loss of normal circadian rhythmicity (18). Both
frq mRNA and FRQ protein are rhythmically expressed in a daily
fashion, and FRQ protein acts to repress the abundance of its
own transcript (17, 19, 20). Importantly, the rhythmic expression
of frq is essential for the negative feedback loop as shown by the
facts that constitutive expression of frq results in the loss of the
overt rhythm and step changes in frq expression reset the phase
of the clock (17). Light and temperature, two of the most
important environmental signals, reset the Neurospora clock by
changing the levels of frq mRNA and FRQ protein (21, 22).
In addition to transcriptional control, frq is subject to several
aspects of posttranscriptional regulation (23). First, two forms of
FRQ protein are expressed because of initiation at alternative
ATGs, a large form of 989 aa (LFRQ) and a smaller form of 890
aa (SFRQ) (19). This mechanism is important for maintaining
optimal clock function over a wide range of temperatures (24).
Phosphorylation of FRQ is another prominent mode of regula-
tion (20). As soon as either form of FRQ protein is made, it is
progressively phosphorylated over time, and its level decreases
after it is extensively phosphorylated. Thus, FRQ is differentially
phosphorylated at different times of day (20), as is the Drosophila
protein PERIOD (3, 25). In Drosophila, the DBT (double-time)
protein, a casein kinase I, acts directly or indirectly to phos-
phorylate the clock protein PER; in a dbt null mutant, PER is
constitutively highly expressed and hypophosphorylated, sug-
gesting that the phosphorylation of PER may lead to its degra-
dation (26, 27).
Protein phosphorylation, as one of the most common types of
protein modifications, has not only been implicated in deter-
mining protein stability (28–30) but has also been shown to
regulate the activity, cellular localization, and DNA- or protein-
binding ability of different proteins (31–33). In this study, we set
out to study the biological function of FRQ phosphorylation and
its role in circadian regulation. We have shown that FRQ
phosphorylation can be blocked by 6-dimethylaminopurine (6-
DMAP), a general kinase inhibitor, and the inhibition of phos-
phorylation by the drug is correlated with a dramatic decrease
in the degradation rate of FRQ protein and lengthening of the
period of the clock in a concentration-dependent fashion. To
establish the connection between FRQ phosphorylation and
effects on the clock, we have identified three phosphorylation
sites and determined that phosphorylation at Ser-513 is impor-
tant for determining the degradation rate of FRQ. These data
demonstrate that FRQ phosphorylation is important for regu-
lating FRQ degradation rate, and that stability of FRQ is a major
determining factor for the period length of the Neurospora
circadian clock.
Materials and Methods
Strains, Culture Conditions, and Race Tube Assay. Neurospora strains
used in this study are bdA (clock wild type), YL15, and different
frq mutant strains (20). Strain YL15 expresses only the small
FRQ (SFRQ) form containing amino acids (aa) 100–989 (20).
The frq null strain 93–4 (bd; frq10 A; his-3) (18) was the host strain
for all frq mutation constructs described. Culture conditions
were as described previously (17, 21). To monitor the degrada-
tion of FRQ protein, a light-to-dark transition (LD) or cyclo-
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heximide (CHX) treatment was used. For LD transitions, the
Neurospora liquid cultures were first grown for at least one day
in constant bright light at 25°C (LL) then transferred into
constant darkness at 25°C. When used, CHX (Sigma) was added
to cultures at a final concentration of 10 mgyml after the cultures
were grown in LL for at least 24 hr, and the cultures were kept
in LL afterward. The cultures were collected at the indicated
times.
Race tube assay, densitometric analyses of race tubes, and
calculations of period length were performed as described (24).
Plasmid Constructs and Neurospora Transformation. pKAJ120 (con-
taining the whole frq gene and a his-3 targeting sequence) and
pYL15 (a DraIII-SphI deletion of pKAJ120 that allows only the
expression of SFRQ) were the parental plasmids for all other frq
constructs (18, 20). All the deletions and point mutations of the
FRQ ORF were constructed by using the Transformer Site-
Directed Mutagenesis kit (CLONTECH). A SphI-EcoRV frq
fragment containing most of the FRQ ORF from pKAJ120 was
cloned into pUC19, and the resulting plasmid, pUC19Mfrq, was
used as the in vitro mutagenic template. The mutagenic primers
used were FRQ4 (to delete FRQ aa 435–558), FRQ4A (to delete
FRQ aa 435–496), FRQ4B (to delete FRQ aa 500–558), FRQ4C
(to delete FRQ aa 500–519), FRQ4D (to delete FRQ aa
531–558), FRQ501A (to mutate Ser-501 to Ala and Ser-503 to
Gly), 513R (to mutate Ser-513 to Arg and Thr-514 to Ala), 519A
(to mutate Ser-519 to Ala), 513I (to mutate Ser-513 to Ile), 513D
(to mutate Ser-513 to Asp). After mutagenesis, the AflII-BssHII
fragments from the resulting constructs were inserted into
AflII-BssHII-digested pYL15 (which expresses only SFRQ) or
pKAJ120 (which expresses both FRQ forms). Final plasmids
based on pYL15 are named pSFRQ# (e.g., pSFRQ4); if based
on pKAJ120, they are called pFRQ# (e.g., pFRQ501A). All
constructs were confirmed by DNA sequencing and were tar-
geted by transformation to the his-3 locus of strain 93–4, as
previously described (34). For protein analyses, at least three to
four independent transformants were examined. For race tube
analysis, at least 20 independent transformants were examined.
Protein Analysis. Protein extraction, quantification, and Western
blot analysis are as previously described (20). Equal amounts of
total protein ('100 mg) were loaded in each protein lane, and
after the blots were developed by chemiluminescence (enhanced
chemiluminescence, Amersham), they were stained by amido
black to verify equal loading of protein (24). Densitometry of the
signal was performed by using NIH IMAGE 1.61.
Results
6-DMAP Can Block FRQ Phosphorylation in Vivo, Slow Down the
Degradation Rate of FRQ, and Lengthen the Period of the Clock. To
understand the biological function of FRQ phosphorylation, we
tested several kinase inhibitors for their ability to block FRQ
phosphorylation in vivo. 6-DMAP, a general kinase inhibitor
(35), was found to inhibit FRQ phosphorylation in vivo (Fig. 1).
Two different time points about half of a circadian cycle apart
were chosen: constant darkness (DD)14 (14 hr in constant
darkness, corresponding to subjective morning) and DD24 (cor-
responding to subjective evening). DD14 is the time at which the
phosphorylation level of FRQ protein is low, and protein level
is on the rise, whereas at DD24, FRQ is highly phosphorylated
and its level is decreasing (20). As can be seen from the control
lanes (2DMAP) of Fig. 1, FRQ protein is progressively phos-
phorylated (note the gradual mobility shifts of FRQ protein and
the changes in the distribution of different FRQ phosphorylation
forms). These changes in protein mobility are the results of FRQ
phosphorylation events, as shown by the fact that when protein
extracts are treated with l-phosphatase, all bands are converted
into two, representing the large and small forms of FRQ (20).
This progressive phosphorylation is especially apparent for the
DD14 samples. However, in the presence of 5 mM 6-DMAP, the
mobility shifts of FRQ at both time points are substantially
delayed, indicating that phosphorylation is blocked by the drug;
compare the phosphorylation patterns at 4 and 6 hr with and
without the inhibitor. The top two phosphorylation bands are
completely missing in the 1DMAP lanes for the DD14 samples.
Our previous results have suggested that the phosphorylation
of FRQ protein could be important for regulating its degrada-
tion. Rhythmicity is seen not only in the level of the FRQ protein
but also in its phosphorylation state. Moreover, FRQ protein
always becomes extensively phosphorylated before its level starts
to decrease (20). Secondly, after the inhibition of protein
synthesis, FRQ protein becomes highly phosphorylated before
its degradation (24). Because 6-DMAP can block FRQ phos-
phorylation, we wondered about the effect of this inhibition on
FRQ stability. To examine the degradation of FRQ, two differ-
ent kinds of treatment were used: either a simple LD transition
or the addition of the protein synthesis inhibitor CHX (10
mgyml) to the culture. An LD transition results in rapid degra-
dation of frq mRNA and FRQ protein [(11, 21), Fig. 2A], and
resets the clock to subjective dusk (circadian time 12, CT12).
CHX treatment at 10 mgyml was previously shown to block de
novo synthesis of FRQ completely (24, 36). In this study, both
methods were used and gave consistent results.
As shown in Fig. 2 A and B, FRQ is rapidly degraded after the
LD transition. Note the gradual shifts in the phosphorylation
bands with time. However, in the presence of 5 mM 6-DMAP,
the degradation process is significantly reduced: there is still
about 70% of FRQ remaining after 8 hr in DD, compared with
only 10–15% for the control. Consistent with the results in Fig.
1, the phosphorylation process was also effectively slowed down
by the drug treatment; the shift of phosphorylation bands is
much slower than that seen in the control (Fig. 2 A). Similar
results were obtained with and without 6-DMAP in the CHX-
treated culture (data not shown). These results suggest that the
inhibition of FRQ phosphorylation leads to a slower degradation
rate.
Because 6-DMAP treatment slows down FRQ degradation,
we reasoned that the Neurospora circadian clock might also run
more slowly (have a longer period length) in constant darkness
in the presence of the drug. To test this prediction, different
concentrations of 6-DMAP (from 0 to 500 mM) were added to
the race tube medium and the circadian conidiation banding
rhythms monitored in constant darkness. As predicted, the
period length of the conidiation rhythm gradually increases with
increasing concentrations of 6-DMAP, from 21.1 hr (2drug) to
25.5 hr (500 mM 6-DMAP) (Fig. 2C). This result suggests that the
Fig. 1. 6-DMAP blocks FRQ phosphorylation in vivo. At two different
circadian time points, DD14 (CT2, Top) and DD24 (CT13, Bottom), half of the
cultures were treated with 5 mM 6-DMAP. Cultures were harvested at the
indicated times after the treatment. Western blot analysis shows the phos-
phorylation profiles of FRQ protein. The asterisks indicate missing LFRQ
phosphorylation bands in the 6-DMAP treated sample.






phosphorylation-induced degradation of FRQ is an important
element in determining the period length of the circadian clock
in Neurospora. Despite the significant changes in period length,
there is only a small reduction of the growth rate in the cultures
when the drug concentration is less than 200 mM, suggesting that
the period lengthening effect of the drug is not caused by
nonspecific effects resulting in toxicity.
Identification of Three Phosphorylation Sites on FRQ. Although the
data above are consistent with a role of FRQ phosphorylation in
determining its degradation rate, nonspecific side effects of the
drug cannot be excluded. To establish the relationship between
phosphorylation and FRQ stability, it is important to determine
the locations of the pertinent sites and the individual effects of
phosphorylation at those sites. If indeed FRQ phosphorylation
is important for triggering its degradation, the elimination of
certain FRQ phosphorylation sites should stabilize FRQ. To
examine this, we made systematic deletions of '100 aa spanning
the entire ORF of FRQ. We reasoned that if a region containing
phosphorylation sites is deleted, fewer bands should be observed
by Western analysis. Because both the large and small forms of
FRQ are progressively phosphorylated, and it is difficult to
resolve different phosphorylation bands when both forms are
present, all the initial deletions were made in the ORF of the
SFRQ form [aa 100–989 (20)]. All the constructs were trans-
formed into the frq null strain [frq10 (18)]. To examine the
phosphorylation patterns in different strains, cultures were
harvested after about 2 days of growth in LL. Under these
conditions, FRQ protein is evenly phosphorylated, and all
phosphorylation bands can be seen. After analyzing different
deletion mutants (data not shown), we found that deletion of aa
435–558 (SFRQ4) causes a significant reduction in the number
of bands (Fig. 3 A and B), as well as the expected reduction in
molecular weight (compare the SFRQ4 lane to the control lane,
SFRQ). This result suggests that some phosphorylation sites
reside in this deleted region.
To narrow down the region further, two smaller deletions were
made: SFRQ4A (deletion of aa 435–496) and SFRQ4B (deletion
of aa 500–558) (Fig. 3A). Because SFRQ4B was found to have
fewer phosphorylation bands (Fig. 3B), two further deletions
were made within aa 500–558: SFRQ4C (deletion of aa 500–519)
and SFRQ4D (deletion of aa 531–558). As shown in Fig. 3B,
SFRQ4C is phosphorylated to a lesser extent than SFRQ4D and
the wild-type SFRQ, indicating that some phosphorylation sites
are located within this 20-aa region (Fig. 3C).
To identify the phosphorylation sites within this 20-aa region,
its sequence was compared with the corresponding regions of all
other frq homologs (37, 38), and three conserved putative
phosphorylation sites were identified: Thr-501, Ser-513, and
Ser-519 (marked by asterisks in Fig. 3C). To determine whether
these three sites are indeed phosphorylation sites, point muta-
tions were introduced at each position (Fig. 3C). In the T501A
and S513R mutations, an additional Ser or Thr was also mutated.
After transformation of these constructs into the frq null strain,
their phosphorylation patterns were compared with that of the
wild-type SFRQ. As shown in Fig. 3D, the highest molecular
weight band is missing in these three mutants, indicating these
sites are indeed phosphorylation sites.
Fig. 2. 6-DMAP slows down FRQ degradation and lengthens the period of
the Neurospora clock in a dose-dependent manner. (A) Western blot analysis
showing the reduction of FRQ degradation after an LD transition in the
presence of 5 mM 6-DMAP. Cultures were first grown in LL for 1 day before
being transferred into DD. Just before the LD transition, 5 mM 6-DMAP was
added to half of the cultures, and cultures were harvested at the indicated
times in DD. (B) Densitometric analysis of the Western blot shown in A. (C) Race
tube data showing that 6-DMAP lengthens the period of the clock in a
dose-dependent manner. (Left) The concentrations of the drug. Two replicate
race tubes for each concentration are shown.
Fig. 3. Identification of three FRQ phosphorylation sites. (A) Schematic
diagram of SFRQ deletion constructs. The dashed box represents the entire
SFRQ ORF (aa 100–989). The black bars below indicate the locations of the
deleted regions in different sFRQ constructs. ‘‘4’’ denotes sFRQ4; 4A-D repre-
sent subsections of ‘‘4.’’ (B) FRQ phosphorylation profiles in various sFRQ
deletion strains. Cultures were grown in LL for at least 24 hr before harvesting.
* marks the strains in which SFRQ is less phosphorylated than the wild-type
SFRQ. The various FRQ phosphorylation forms were separated by using a
longer than normal electrophoresis time to emphasize the mobility differ-
ences caused by phosphorylation. (C) The sequence of the 20-aa region
deleted in sFRQ4C. The three potential phosphorylation sites conserved
among different fungal frq homologs are indicated by *. The point mutations
introduced are described in parentheses. (D) SFRQ phosphorylation profiles of
the mutants containing point mutations at the three potential sites. The arrow
indicates the phosphorylation band missing in the three mutants.
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FRQ Phosphorylation Site at Ser-513 Is Important for Regulating FRQ
Degradation Rate. To examine whether these mutations affect
degradation of SFRQ, CHX was added and the degradation of
SFRQ monitored by Western blot analysis. As shown in Fig. 4A,
the deletion of region 4C dramatically reduced the degradation
rate of SFRQ. The T501A and S519A mutations did not appear
to significantly affect the degradation rate of SFRQ; on the other
hand, the S513R mutation resulted in a dramatic reduction in the
degradation rate, suggesting that the phosphorylation site at aa
513 is important for regulating FRQ degradation. The different
effects of these three mutations clearly indicate that not all FRQ
phosphorylation sites are created equal, and certain sites are
more important than others for determining the stability of
FRQ.
The slow degradation of FRQ has been predicted to have a
major role in determining the long period of the circadian
oscillation (19). If so, we would predict that the slow degradation
of FRQ in the S513R mutant would result in a strain having a
substantially longer period than that of the wild type. To test this
prediction, these mutations were introduced into constructs that
contain both FRQ forms (because both forms are required for
an optimally running clock) (24). The constructs were trans-
formed into the frq null strain, and the resultant clock pheno-
types monitored by race tube assays (Fig. 4B). As predicted, the
period length of the S513R mutant ('31 hr) is about 50% longer
than that of the wild type. Consistent with these results, the
degradation rate of FRQ after an LD transition is slower in the
513R mutant than in the wild type (Fig. 4 C and D). Note that
after '8 hr in DD, the wild-type FRQ has already reached the
trough level, whereas FRQ in the 513R mutant is still in the
middle of the degradation process. After 12 hr, the newly
synthesized and less phosphorylated wild-type FRQ has begun to
appear, whereas the mutant protein is still in the process of decay
(Fig. 4C). The T501A and S519A mutations also have period
effects, but because of the sensitivity of the Western blot analysis
and the small period differences, it is unclear whether these
effects are related to their influence on FRQ degradation.
Although the above data strongly suggest that the phosphor-
ylation site at Ser-513 is important for triggering FRQ degra-
dation, it is not clear whether Ser-513 is indeed responsible for
the effects because the S513R mutant has two point mutations,
513S-R and 514T-A [Thr-514 is not conserved among different
frq homologs (38)] (Fig. 3C). To clarify this matter and also to
show the involvement of phosphorylation in FRQ degradation,
two different mutations were made at Ser-513. One mutation
changes Ser-513 to an isoleucine (I), and another mutation
changes it to an acidic aa (aspartic acid, D), because it has been
shown that acidic aa can mimic the effect of phosphorylation in
some cases (30). If indeed Ser-513 is a phosphorylation site
responsible for controlling FRQ stability, the S513I and S513R
mutations should exhibit similar phenotypes, and the FRQ
degradation rate should be slower in S513I mutants than in the
S513D mutant if the aspartic acid can mimic a phosphorylated
aa.
As shown in Fig. 5A, the disappearance of the top phosphor-
ylation band in both SFRQ513I and SFRQ513D strains indicates
that Ser-513 is indeed a phosphorylation site. As predicted, the
degradation rate of SFRQ513I after the addition of CHX is
dramatically reduced (Fig. 5 B and C), a result that is very similar
to what has been shown for the SFRQ513R mutant (Fig. 4A).
Additionally, as we predicted, the introduction of an acidic
Fig. 4. The effects of deletion and mutation of the FRQ phosphorylation sites
on FRQ degradation and the circadian clock. (A) Western blot analysis showing
that deletion of region 4C (aa 500–519) and mutation of S513 slow down the
degradation of SFRQ. After the cultures were grown in LL for a day, 10 mgyml
of CHX was added at time 0. The appearance of more compact FRQ signals
(compared with FRQ signals in Fig. 3 B and D) was the result of a shorter
electrophoresis time. (B) The densitometric analysis of the race tube data
showing that S513R mutations dramatically increase the period of the clock in
DD. In contrast to the strains used in A, these strains are derived from a
wild-type frq gene and produce both LFRQ and SFRQ forms. (C and D) Western
blot and densitometric analyses showing that S513R mutations slow down
FRQ degradation after an LD transition.
Fig. 5. Two different mutations at S513 result in differential responses of
FRQ degradation. (A) Western blot analysis showing that the S513I and S513D
mutations lead to the loss of the top SFRQ phosphorylation band. The arrow
indicates the missing band in the mutants. (B) Western blot analysis showing
that the S513I mutation dramatically slows down the degradation of SFRQ.
Cultures were grown in LL for a day before CHX was added at time 0. (C)
Grouped data showing densitometric analysis of Western blots from three
independent experiments as in B. Bars 5 SD.






residue is able to mimic the effect of phosphorylation to some
degree, because the degradation rate of SFRQ513D is faster
than that of SFRQ513I. However, SFRQ513D still degrades
more slowly than the wild-type SFRQ (Fig. 5 B and C). This
experiment was carried out three times with similar results,
which are summarized in Fig. 5C.
To examine the clock phenotypes of these mutations, they
were introduced into constructs that encode both FRQ forms,
and after transformation into a frq null strain, their rhythms were
monitored in DD. Similar to the results shown in Fig. 5 B and C,
the degradation rate of FRQ after an LD transition is much
slower in the S513I mutant than in both the wild-type and the
513D strain (Fig. 6 A and B). As expected, the period of the S513I
mutant ('35 hr) is much longer than that of the wild-type and
KAJ120 (bearing a wild-type frq gene transformed into the his-3
locus of a frq10 strain) (Fig. 6C); in fact, this mutant has the
longest period of all of the frq mutants known to date (39).
However, to our surprise, the conidiation process in the 513D
mutant appears to be arrhythmic. The loss of rhythmicity in the
513D strain must be caused by the loss of proper regulation of
the FRQ negative feedback process and suggests the possibility
that this part of FRQ may be involved in aspects of function
beyond regulating stability.
Taken together, the data presented here demonstrate that the
phosphorylation of FRQ is important for regulating its degra-
dation, and the stability of FRQ is an important factor in
determining the period length of the Neurospora clock.
Discussion
Previous studies have shown that the frq gene is one of the central
components of a Neurospora negative feedback loop that deter-
mines the period length and temperature compensation char-
acteristics of the circadian clock (17, 18, 40). In this study, we
investigated the biological role of FRQ phosphorylation, and
several lines of evidence were presented consistent with phos-
phorylation regulating FRQ stability. First, we showed that a
kinase inhibitor, 6-DMAP, can slow FRQ phosphorylation in
vivo; it also slows FRQ degradation and lengthens the period of
the Neurospora circadian clock. Second, by systematic mutagen-
esis of the FRQ ORF, three FRQ phosphorylation sites were
identified. Subsequent elimination of the phosphorylation site at
Ser-513 leads to a dramatic reduction in the rate of FRQ
degradation and a significantly increased period. Finally, we
have also shown that an acidic aa at residue 513 speeds the
degradation of FRQ probably by mimicking the phosphoryla-
tion. Taken together, these data strongly suggest that phosphor-
ylation triggers the degradation of FRQ, and that the degrada-
tion rate is a determining factor for the period length of the
Neurospora circadian clock. Despite the existence of additional
phosphorylation sites, Ser-513 appears to be one of the main sites
for determining the degradation rate of FRQ.
Interestingly, phosphorylation appears to play a similar role
for a Drosophila clock protein, PER, which is also progressively
phosphorylated over time. DBT, a casein kinase I homolog, leads
either directly or indirectly to the phosphorylation and degra-
dation of PER, because PER is hypophosphorylated in a dbt null
strain where its level is constitutively high (26, 27). Neurospora
contains at least two casein kinase I homologs, which are
presently being examined for roles in FRQ phosphorylation.
A major implication of this study is that the degradation of a
central clock component is essential for the proper functioning
of the clock. If we look at a clock following the expression of its
central components, we can view one circadian cycle as two
halves (19). One half is the activation and accumulation of clock
transcripts and proteins, and the other half is the inhibition and
the degradation of those transcripts and proteins. Each process
is essential for proper clock function, and the speed of each
process is what determines the period length of the clock. In
Neurospora, the activation process possibly involves the products
of wc-1 and wc-2, which initiate every new cycle by activating the
expression of frq mRNA and FRQ protein. The other half of the
cycle is a combination of the negative feedback on frq transcript
levels by its own protein and the degradation process of frq
mRNA and FRQ protein (1, 11, 20). In this study, we have shown
that the degradation of FRQ protein is indeed one of the key
factors affecting the Neurospora circadian system, and the rate of
FRQ degradation is a major determinant for the period length
of the clock. The noncircadian fluctuations or oscillations that
exist in the absence of FRQ (e.g., 18, 42, 43) are rendered
circadian in nature by coupling to the FRQyWC feedback loop,
and these data on FRQ phosphorylation reemphasize the es-
sential role of the FRQyWC loop in establishing the circadian
characteristics of this rhythmic system. In similar studies, Price
and coworkers have shown that two alleles of Drosophila dbt
(dbtS and dbtL) change the period of the clock presumably by
affecting the degradation of PER (26, 27). Similarly, in the
dinoflagellate Gonyaulax polyedra, various protein kinase inhib-
itors have been shown to affect circadian rhythmicity (35, 41).
Interestingly, the same kinase inhibitor we have used, 6-DMAP,
has been shown to have a period-lengthening effect, suggesting
phosphorylation also plays a role in the Gonyaulax clock. How-
ever, because of the lack of specificity of the drug and its
unknown effects on the clock components of Gonyaulax, we
cannot be sure that a mechanism similar to the one we have
shown in Neurospora also exists in Gonyaulax.
As can be seen from its phosphorylation pattern, FRQ is
phosphorylated at multiple sites. The three sites identified in this
study represent only a portion of the sites, because when the
region containing all three sites is deleted, multiple FRQ
phosphorylation bands can still be seen (Fig. 3B). Although it is
clear that Ser-513 is one of the major phosphorylation sites
responsible for triggering FRQ degradation, it cannot be that
Fig. 6. The S513I mutation results in significantly slower FRQ degradation
and in a very long circadian period. (A) Western blot analysis of FRQ degra-
dation after an LD transition in the wild-type and the two S513 mutant strains.
The numbers above the blot indicate the number of hours after the LD
transition. (B) Densitometric analysis of Western blots from three indepen-
dent experiments as in A. Bars 5 SD. (C) Race tube data of the wild-type,
KAJ120, and S513 mutant strains. The first black bar on each race tube
indicates the time of the LD transfer. The subsequent black bars indicate the
growth fronts of the cultures every 24 hr. The periods of the strains are shown
on the right. ARR, arrhythmic.
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Ser-513 is the only important site for degradation because the
clock still runs, albeit aberrantly, in the 513I mutant strain.
Furthermore, it is also quite possible that the phosphorylation of
other sites is involved in other aspects of FRQ function, such as
nuclear localization (44) or protein activity. The slightly shorter
period of the 519A strain suggests that the phosphorylation site
at Ser-519 is not responsible for triggering FRQ degradation,
although this site may be involved in other types of regulation
(Fig. 4 A and B).
Another implication of our results is that, despite the pro-
gressive appearance of the FRQ phosphorylation pattern sug-
gesting that the phosphorylation events might be sequential (i.e.,
the phosphorylation of one site leads to the phosphorylation of
another), the phosphorylation patterns of our mutants suggest
this is not the case for all of these phosphorylation sites. The
elimination of some sites does not appear to affect the phos-
phorylation of others (Figs. 3D and 5A); therefore, phosphory-
lation events at different positions in the protein are likely to be
independent of one another.
Circadian clocks control a wide variety of cellular activities
with a remarkable degree of precision under constant condi-
tions. To achieve such precision, various types of posttranscrip-
tional and posttranslational regulation are required. In Neuro-
spora, the phosphorylation of FRQ and its subsequent degra-
dation are important for generating the circadian oscillations in
the abundance of frq mRNA and FRQ proteins, which are
essential for normal circadian rhythmicity. Together with other
types of transcriptional and posttranscriptional regulation, they
provide a variety of facets where regulatory elements might
influence the operation of the clock.
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